STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression.

• Sponsor: NeuroRx, Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02974010
• Collaborator: Massachusetts General Hospital (Other), Target Health Inc. (Industry)
• Enrollment: 22
• Locations: 4
• Arms: 2
• Actual Duration (Months): 22.1
• Patients Per Site: 5.5
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or 5) or Behavior (ASIB) in following initial stabilization. Patients with Severe Bipolar Depression and ASIB will be recruited in both inpatient and outpatient settings and, following informed consent, will be given an intravenous infusion of ketamine 0.5mg/kg over 40 minutes. Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone alone (the comparator group). This study is conducted as a feasibility study for a pivotal phase 2b/3 clinical trial and the primary outcomes for this phase 2 study were blood levels of NRX-101, in order to confirm pharmaco-kinetics with remission from depression, as measured by BISS-derived MADRS and relapse as secondary outcomes.

Condition or Disease	Intervention/Treatment	Phase
Bipolar Depression; Suicidal Ideas; Suicidal Ideation; Suicide, Attempted	Drug: NRX-101 Oral Capsule; Drug: Lurasidone Oral Capsule; Drug: Ketamine Intravenous Infusion; Drug: Saline Solution Intravenous Infusion	Phase 2

Detailed Description

NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of D-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation or Behavior (ASIB) in adults with Bipolar Depression following initial stabilization with ketamine. In recent years, intravenous and intranasal ketamine have demonstrated rapid and potent effects in achieving remission from both depression and suicidal ideation in both bipolar depression and major depressive disorder. However ketamine is will understood to induce hallucination and other dissociative side effects, to be addictive and have high abuse potential, and to have potential neurotoxic effects. Moreover, ketamine can only be administered in a monitored hospital or clinic setting. NRX-101 was developed with the objective of seeking a safe, non-hallucinogenic, non-addictive, oral medication that might maintain the effects of ketamine in patients with severe depression and acute suicidal ideation and which might be considered as initial therapy for patients with depression and non-acute suicidal ideation. The D-cycloserine component of NRX-101 is believed to act by inhibiting the brain's NMDA receptor and raising levels of glutamate/glutamine (Glx) in the anterior cingulate cortex. Increased Glx, as measured by magnetic resonance spectroscopy, has been associated with clinical improvement following electroconvulsive therapy (ECT) and following administration of IV ketamine.

The proposed oral combination product is intended to be administered as part of a sequential therapy consisting of the following 2 components:

1. an initial, one-time intravenous (iv) infusion of ketamine (0.5 mg/kg administered over 40 min), followed one day later by

2. twice daily oral capsules of NRX 101 (DCS + lurasidone), dosing of which is initiated 1 day after ketamine administration, titrated over 5 days to a maintenance dose and continued for up to 6 weeks. Each NRX-101 oral capsule contains DCS (237.5 or 175.0 mg) and lurasidone (8.25, 16.5, or 33.0 mg). It is anticipated that subjects entering the study will be receiving concurrent disorder-directed treatment with other approved medications. This treatment regime will be maintained upon entry into the study. However, any use of lurasidone, quetiapine, or olanzapine will be stopped at study entry, so as to avoid either duplication with study drug (groups 1 and 2) or undermining of the control group.

The clinical efficacy goal is to provide extended relief from symptoms associated with Severed Bipolar Depression and ASIB in adults with Bipolar Disorder, after initial stabilization with iv ketamine in a clinic, emergency department, or inpatient setting.

The proposed NRX-101 product takes advantage of a unique synergistic confluence of combining two active pharmaceutical ingredients (DCS and lurasidone) that respectively inhibit the NMDA and the D2/5-HT2A receptors in the brain. NMDA receptor antagonists, most notably ketamine, have been shown in many studies to rapidly reduce depressive and suicidal ideation. However, numerous studies have demonstrated the potential of NMDA antagonists to cause hallucination and other dissociative side effects. Similarly, D2/5HT2A receptor antagonists, such as lurasidone have demonstrated antidepressant effects in bipolar depression, but have demonstrated a propensity to cause akathisia in some patients. The goals of combining these drugs into a single course of treatment is to maximize the beneficial effects of the specific subcomponents while overcoming potential treatment-limiting side effects associated with those subcomponents.

Beneficial effects of the proposed dosage regimen include 1) well-documented pharmacodynamic effects of ketamine in treating both persistent depressive symptoms and suicidal ideation in bipolar disorder (McCloud, 2015; Naughton, 2014; Newport, 2015; Price, 2014), 2) well-documented pharmacodynamic effects of oral DCS against persistent symptoms of depression (Heresco-Levy, 2013) and 3) the FDA-approved efficacy of lurasidone in treatment-resistant depression (Sunovion Pharmaceuticals, 2013). Due to the synergistic effects, the proposed NRX-101 combination capsule is also expected to avoid or minimize the significant undesired adverse effects associated with the usage of these drugs as single agents (eg, negative consequences of repeated use of ketamine (JHP Pharmaceuticals, 2012), potential psychotomimetic effects of long-term treatment with DCS alone (Kantrowitz, 2010) and potential akathisia and susceptibility for increased suicidality associated with lurasidone alone (Sunovion Pharmaceuticals, 2013).

The risk of ASIB is higher in bipolar depression than other psychiatric disorder and the majority of currently available antidepressants are contraindicated for patients with bipolar depression. NeuroRx believes that the proposed NRX-101 treatment regimen (ketamine administration followed by NRX-101) will demonstrate superiority over ketamine followed by lurasidone in maintaining remission from depression and in delaying the time to documented relapse from depression and suicidality in bipolar disorder, providing a new treatment option for patients with Severe Bipolar Depression and ASIB.

There is currently no FDA-approved product for the treatment of ASIB. NeuroRx proposes that NRX-101 will fulfill an urgent medical need for safe and effective treatment for ASIB.

Patients with Severe Bipolar Depression and ASIB will be recruited in inpatient settings and, following informed consent, will be given an intravenous infusion of either ketamine 0.5mg/kg over 40 minutes or normal saline (placebo). Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone along (the comparator group). The primary outcome variable for this phase 2 study will be blood level (pharmacokinetic) exposure of NRX-101 and its D-cycloserine component with remission from depression, as measured on the MADRS scale and relapse as secondary endpoints. Relapse is defined as return of either depression or suicidality OR the need to alter therapy, which might include re-hospitalization, additional antidepressant medication, or electroconvulsive therapy (ECT).

Study Design

• Study Type: Interventional
• Actual Enrollment: 22 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study
• Actual Study Start Date: Jan 15, 2018
• Actual Primary Completion Date: Aug 31, 2018
• Actual Study Completion Date: Nov 20, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: NRX-101 NRX-101 is a fixed dose combination of d-cycloserine and lurasidone	Drug: NRX-101 Oral Capsule; Prospective Randomized Factorial Design Study as per arm/group descriptions; Other Names: D-cycloserine + Lurasidone Fixed Dose Combination ; Drug: Ketamine Intravenous Infusion; Randomized administration of Ketamine or Placebo in a 3 to 1 ratio; Drug: Saline Solution Intravenous Infusion; Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Active Comparator: Lurasidone Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101	Drug: Lurasidone Oral Capsule; Prospective Randomized Factorial Design Study as per arm/group descriptions; Other Names: Lurasidone Fixed Dose Combination ; Drug: Ketamine Intravenous Infusion; Randomized administration of Ketamine or Placebo in a 3 to 1 ratio; Drug: Saline Solution Intravenous Infusion; Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

Outcome Measures

Primary Outcome Measures

1. BDM Score (BISS-derived MADRS) Change From Baseline at Day 42 [Day 42]

   The study will measure the difference on BISS-derived MADRS score between NRX-101 and lurasidone (comparator) groups. The Bipolar Inventory of Symptom Scale (BISS) is a validated 42-item clinician-rated scale (21 items each for the depression and mania subscales) in which each item is rated on a 0-4 severity scale where higher values indicate worse severity. BISS-derived MADRS (BDM): MADRS is a 10-item clinician-rated scale, with each item rated on a 0-6 severity scale, where a higher number indicates worse severity. Responses to each question are equally weighted and summed. The BDM has a minimum score of 0 and a maximum of 40, where higher scores indicate a worse severity, therefore decreases in average BDM are considered a better outcome. Data are presented as mean change from baseline (end of stage 1, Day 1) using LOCF

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:A subject will be eligible for inclusion in this study only if all of the following criteria apply:

1. Male or female, 18 to 65 years of age, inclusive, at screening.

2. Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about AEs and other clinically important information.

3. Diagnosed with Bipolar Disorder (BD) according to the criteria defined in the DSM-5. The diagnosis of BD will be made by a site psychiatrist and supported by the MINI 7.0.2. The diagnosis will be confirmed by remote, independent raters, via teleconference between the screen visit and the baseline visit.

4. Suicidal ideation or behavior of sufficient severity to meet the requirements for a score of 4, or 5 on the C-SSRS (suicide attempt, interrupted attempt, aborted attempt, preparatory actions toward imminent suicidal behaviors, active method, intent +/- plan).

5. A score equal to or greater than 20 on the MADRS items of the BISS.

6. In good general health, in the opinion of the investigator, as ascertained by medical history, physical examination (PE) (including measurement of seated vital signs), clinical laboratory evaluations, and electrocardiogram (ECG).

7. If female, a status of non-childbearing potential or use of an acceptable form of birth control per the following specific criteria:

1. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized [status post hysterectomy, bilateral tubal ligation], or is post-menopausal with her last menses at least one year prior to screening); or

• Childbearing potential, and meets the following criteria:

• Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent.

• Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test at randomization prior to receiving study treatment.

• Willing and able to continuously use one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline.

1. Body mass index between 18-35 kg/m2.

2. Concurrent psychotherapy will be allowed if the type (e.g., supportive, cognitive behavioral, insight-oriented) and frequency (e.g., weekly or monthly) of the therapy has been stable for at least three months prior to screening and if the type and frequency of the therapy is expected to remain stable during the course of the subject's participation in the study.

3. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, benzodiazepines or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the subject's participation in the study. Subjects can also continue treatment with benzodiazepines used for sleep or anxiety if therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the subject's participation in the study.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

1. Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.

2. Female that is pregnant or breastfeeding.

3. Female with a positive pregnancy test at screening or baseline.

4. Current diagnosis of a substance use disorder (abuse or dependence, as defined by DSM-5, with the exception of nicotine dependence), at screening or within 6 months prior to screening.

5. Current Axis I disorder, diagnosed at screening with the use of the MINI 7.0.2, that is the primary focus of treatment and BD the secondary focus of treatment for the past 6 months or more.

6. History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms.

7. History of anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified, within 5 years of screening.

8. Any Axis I or Axis II Disorder, which at screening is clinically predominant to their BD or has been predominant to their BD at any time within 6 months prior to screening.

9. Has dementia, delirium, amnestic, or any other cognitive disorder.

10. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study clinician.

11. Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.

12. Current episode of:

• Hypertension, Stage 1 as defined by a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening on two of three measurements at least 15 minutes apart.

• Hypertension, Stage 1 as defined by a systolic blood pressure ≥155 mmHg or diastolic blood pressure ≥99 mmHg at the Baseline Visit (Visit 1) within 1.5 hours prior to ketamine infusion on two of three measurements at least 15 minutes apart.

• Recent myocardial infarction (within one year) or a history of myocardial infarction.

• Syncopal event within the past year.

• Congestive heart failure (CHF) New York Heart Association Criteria >Stage 2

• Angina pectoris.

• Heart rate <50 or >105 beats per minute at screening or randomization (Baseline Visit).

• QTcF (Fridericia-corrected) ≥450 msec at screening or randomization (Baseline Visit).

1. Current history of hypertension, or on antihypertensives for the purpose of lowering blood pressure, with either an increase in antihypertensive dose or increase in the number of antihypertensive drugs used to treat hypertension over the last 2 months.

2. Chronic lung disease excluding asthma.

3. Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, or any other disease/procedure/accident/intervention which, according to the screening clinician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years.

4. Presents with any of the following lab abnormalities:

• Subjects with diabetes mellitus fulfilling any of the following criteria:

• Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) >8.5% at screening.

• Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus-related illness in the past 12 weeks.

• Not under physician care for diabetes mellitus.

• Has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to screening. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.

• Any other clinically significant abnormal laboratory result (determined as such by the investigator and medical monitor) at the time of the screening.

1. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.

2. Positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates.

3. Subjects with exclusionary laboratory values, or requiring treatment with exclusionary concomitant medications as defined in the study manual

4. Subjects on exclusionary concomitant psychotropic medications.

5. Subjects with a lifetime history of illicit PCP/ketamine drug use or previous failed use of ketamine for depression.

6. Liver Function Tests higher than 2.5 times upper limit of normal as defined in the study manual.

7. Known allergies to Lurasidone or Latuda, Cycloserine or Seromycin, Mannitol, Croscarmellose Sodium, Magnesium Stearate, Silicon Dioxide, and/or HPMC (hydroxypropylmethylcellulose)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site, Birmingham	Birmingham	Alabama	United States	35294
2	Research Site, Fort Lauderdale	Fort Lauderdale	Florida	United States	33024
3	Research Site, Charlotte	Charlotte	North Carolina	United States	28211
4	Research Site, Houston	Houston	Texas	United States	77030

Sponsors and Collaborators

• NeuroRx, Inc.
• Massachusetts General Hospital
• Target Health Inc.

Investigators

• Principal Investigator: Andrew Nierenberg, MD, Massachusetts General Hospital
• Study Director: Daniel C Javitt, MD, NeuroRx, Inc.

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Nov 17, 2016

More Information

Publications

None provided.

• Responsible Party: NeuroRx, Inc.
• ClinicalTrials.gov Identifier: NCT02974010
• Other Study ID Numbers: NRX 101-001
• First Posted: Nov 28, 2016
• Last Update Posted: May 25, 2021
• Last Verified: May 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by NeuroRx, Inc.: d-cycloserine; lurasidone; ketamine; randomized controlled trial
• Additional relevant MeSH terms: Depression; Depressive Disorder; Suicide; Bipolar Disorder; Suicidal Ideation; Suicide, Attempted; Cycloserine; Ketamine; Lurasidone Hydrochloride

Study Results

Participant Flow

Arm/Group Title	Ketamine Followed by NRX-101	Ketamine Followed by Lurasidone	Saline Followed by NRX-101	Saline Followed by Lurasidone
Arm/Group Description	NRX-101 is a fixed dose combination of d-cycloserine and lurasidone NRX-101 Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Period Title: Overall Study
STARTED	12	5	4	1
COMPLETED	6	2	2	1
NOT COMPLETED	6	3	2	0

Baseline Characteristics

Arm/Group Title	Ketamine Followed by NRX-101	Ketamine Followed by Lurasidone	Saline Followed by NRX-101	Saline Followed by Lurasidone	Total
Arm/Group Description	NRX-101 is a fixed-dose combination of d-cycloserine and lurasidone NRX-101 Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Total of all reporting groups
Overall Participants	12	5	4	1	22
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	33.9 (10.5)	49 (8.9)	41 (8.9)	54 (0)	39.5 (11.43)
Sex: Female, Male (Count of Participants)
Female	9 75%	4 80%	2 50%	1 100%	16 72.7%
Male	3 25%	1 20%	2 50%	0 0%	6 27.3%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	1 8.3%	0 0%	1 25%	1 100%	3 13.6%
White	11 91.7%	5 100%	3 75%	0 0%	19 86.4%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	12 100%	5 100%	4 100%	1 100%	22 100%
Columbia Suicide Severity Rating Scale (CSSRS) (participants) [Number]
CSSRS = 1	1 8.3%	0 0%	0 0%	0 0%	1 4.5%
CSSRS = 2	0 0%	0 0%	0 0%	0 0%	0 0%
CSSRS =3	0 0%	0 0%	0 0%	0 0%	0 0%
CSSRS =4	2 16.7%	0 0%	0 0%	0 0%	2 9.1%
CSSRS = 5	9 75%	5 100%	4 100%	1 100%	19 86.4%

Outcome Measures

1. Primary Outcome

Title	BDM Score (BISS-derived MADRS) Change From Baseline at Day 42
Description	The study will measure the difference on BISS-derived MADRS score between NRX-101 and lurasidone (comparator) groups. The Bipolar Inventory of Symptom Scale (BISS) is a validated 42-item clinician-rated scale (21 items each for the depression and mania subscales) in which each item is rated on a 0-4 severity scale where higher values indicate worse severity. BISS-derived MADRS (BDM): MADRS is a 10-item clinician-rated scale, with each item rated on a 0-6 severity scale, where a higher number indicates worse severity. Responses to each question are equally weighted and summed. The BDM has a minimum score of 0 and a maximum of 40, where higher scores indicate a worse severity, therefore decreases in average BDM are considered a better outcome. Data are presented as mean change from baseline (end of stage 1, Day 1) using LOCF
Time Frame	Day 42

Outcome Measure Data

Analysis Population Description

Last Observation Carrier Forward

Arm/Group Title	Ketamine Followed by NRX-101	Ketamine Followed by Lurasidone	Saline Followed by NRX-101	Saline Followed by Lurasidone
Arm/Group Description	NRX-101 is a fixed-dose combination of d-cycloserine and lurasidone NRX-101 Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio	Saline (stage 1) followed by NRX-101 (stage 2)	Saline (stage 1) followed by lurasidone (stage 2)
Measure Participants	12	5	4	1
Day 2	3.3 (1.95)	2.4 (2.95)	-1.06 (3.81)	0 (0)
Day 7	2.0 (1.91)	4.8 (2.95)	-0.5 (3.74)	0 (0)
Day 14	2.2 (1.91)	11.4 (2.95)	0.31 (4.0)	0 (0)
Day 21	4.5 (1.91)	10.0 (2.95)	1.0 (5.72)	0 (0)
Day 28	3.5 (1.91)	11.2 (2.95)	1.69 (7.34)	0 (0)
Day 35	2.8 (1.91)	10.8 (2.95)	1.75 (8.43)	0 (0)
Day 42	3.7 (1.91)	11.0 (2.95)	0.38 (5.77)	0 (0)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Ketamine Followed by NRX-101, Ketamine Followed by Lurasidone
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	.03
	Comments	BDM LS difference overall
	Method	Mixed Models Analysis
	Comments	BDM LS difference overall

Adverse Events

Time Frame	Study Duration (6 weeks)
Arm/Group Title	Ketamine Followed by NRX-101		Ketamine Followed by Lurasidone		Saline Followed by NRX-101		Saline Followed by Lurasidone
Arm/Group Description	NRX-101 is a fixed-dose combination of d-cycloserine and lurasidone NRX-101 Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio		Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio		Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio		Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101 Lurasidone Oral Capsule: Prospective Randomized Factorial Design Study as per arm/group descriptions Ketamine Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio Saline Solution Intravenous Infusion: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
All Cause Mortality
	Ketamine Followed by NRX-101		Ketamine Followed by Lurasidone		Saline Followed by NRX-101		Saline Followed by Lurasidone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/12 (0%)		0/5 (0%)		0/4 (0%)		0/1 (0%)
Serious Adverse Events
	Ketamine Followed by NRX-101		Ketamine Followed by Lurasidone		Saline Followed by NRX-101		Saline Followed by Lurasidone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/12 (0%)		0/5 (0%)		0/4 (0%)		0/1 (0%)
Other (Not Including Serious) Adverse Events
	Ketamine Followed by NRX-101		Ketamine Followed by Lurasidone		Saline Followed by NRX-101		Saline Followed by Lurasidone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/12 (66.7%)		3/5 (60%)		4/4 (100%)		1/1 (100%)
Cardiac disorders
angina pectoris	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
palpitations	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
Ear and labyrinth disorders
tinnitus	0/12 (0%)	0	3/5 (60%)	3	0/4 (0%)	0	0/1 (0%)	0
tinnitus	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
Eye disorders
Diplopia	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Vision blurred	1/12 (8.3%)	1	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
vision blurred	2/12 (16.7%)	2	1/5 (20%)	1	1/4 (25%)	1	0/1 (0%)	0
Gastrointestinal disorders
Diarrhea	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
Dry mouth	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
nausea	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
vomiting	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
abdominal distention	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
diarrhea	1/12 (8.3%)	1	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
dyspepsia	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
gastroesophageal reflux disease	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
nausea	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
General disorders
fatigue	2/12 (16.7%)	3	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Infections and infestations
vulvovaginal candidiasis	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Injury, poisoning and procedural complications
thermal burn	1/12 (8.3%)	2	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
wound	0/12 (0%)	0	0/5 (0%)	0	0/4 (0%)	0	1/1 (100%)	1
Investigations
weight increased	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Musculoskeletal and connective tissue disorders
muscle spasms	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
Nervous system disorders
coordination abnormal	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
Dizziness	0/12 (0%)	0	2/5 (40%)	3	0/4 (0%)	0	0/1 (0%)	0
dysmetropsia	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
headache	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
hypoasthesia	0/12 (0%)	0	2/5 (40%)	2	0/4 (0%)	0	0/1 (0%)	0
akathisia	1/12 (8.3%)	3	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
hypersomnia	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
lethargy	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
sedation	2/12 (16.7%)	2	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
somnolence	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Psychiatric disorders
Dissociation	2/12 (16.7%)	2	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
euphoric mood	2/12 (16.7%)	2	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
restlessness	1/12 (8.3%)	1	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
anorgasmia	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
depressed mood	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
depression	0/12 (0%)	0	1/5 (20%)	1	1/4 (25%)	1	0/1 (0%)	0
restlessness	2/12 (16.7%)	4	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
suicidal ideation	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	1/1 (100%)	1
Renal and urinary disorders
acute kidney injury	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
Reproductive system and breast disorders
ejaculation delayed	0/12 (0%)	0	0/5 (0%)	0	1/4 (25%)	1	0/1 (0%)	0
Skin and subcutaneous tissue disorders
dry skin	0/12 (0%)	0	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0
rash	1/12 (8.3%)	1	0/5 (0%)	0	0/4 (0%)	0	0/1 (0%)	0
Vascular disorders
hypertension	2/12 (16.7%)	2	1/5 (20%)	1	0/4 (0%)	0	0/1 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.